LitCovid-sample-sentences  

PMC:7441788 / 23288-28508 JSONTXT 24 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T170 0-85 Sentence denotes Several trials evaluated the efficacy of HCQ for the treatment of COVID-19 (Table 1).
T171 86-238 Sentence denotes In a randomized clinical trial from Wuhan about HCQ treatment of mild COVID-19 [50], 31 out of 62 patients received HCQ (200 mg/2 times/day for 5 days).
T172 239-594 Sentence denotes The results showed that the temperature recovery time in the HCQ group was improved compared with the control group (average days, 2.2 vs. 3.2); the cough relief time was shorter in the HCQ group than the control group (average days, 2.4 vs. 3.1); and the improvement rate of pneumonia in the HCQ group was higher than the control group (80.6% vs. 54.8%).
T173 595-757 Sentence denotes However, only 48% of patients (15/31) in HCQ group and 71% of patients (22/31) in control group had cough at baseline and the duration of cough was not described.
T174 758-834 Sentence denotes Improvement of symptoms were small and the trial was terminated prematurely.
T175 835-929 Sentence denotes These factors and the low sample size compromise the reliability of the results of this study.
T176 930-1136 Sentence denotes Importantly, evaluation of HCQ in the COVID-19 pandemic areas have shown that HCQ can help patients with mild symptoms, and may potentially reduce transmission in areas lacking isolation facilities [51,52].
T177 1137-1321 Sentence denotes However, in areas with strict isolation standards, the use of HCQ to reduce transmission or for treatment of mild COVID-19 cases may not be beneficial in risk-benefit analysis [51,52].
T178 1322-1447 Sentence denotes Nevertheless, there is an urgent need for drugs and therapeutics in severe cases, which require randomized controlled trials.
T179 1448-1574 Sentence denotes A study from four French tertiary care centers included 181 patients hospitalized for COVID-19 and requiring oxygen (2 L/min):
T180 1575-1689 Sentence denotes 84 patients received HCQ (600 mg/day) within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group) [53].
T181 1690-1875 Sentence denotes The results showed that the patients transferred to the ICU or died within 7 days and developed ARDS within 7 days had no significant differences between the HCQ group and no-HCQ group.
T182 1876-1969 Sentence denotes Eight patients in the HCQ group (9.5%) discontinued HCQ due to electrocardiogram alterations.
T183 1970-2084 Sentence denotes These results do not support the use of HCQ for treating hospitalized COVID-19-related hypoxic pneumonia patients.
T184 2085-2292 Sentence denotes It is worth noting that in the study’s propensity score model, four possible important prognostic variables were unbalanced and a center effect was not considered, which all can cause bias for study results.
T185 2293-2587 Sentence denotes In a multicenter, randomized, parallel trial about HCQ in patients with mainly mild to moderate COVID-19 [54], 80 patients received ‘standard care’ and 70 patients received HCQ (1200 mg daily for 3 days, and then 800 mg daily for 2 weeks [mild to moderate disease] or 3 weeks [severe disease]).
T186 2588-2741 Sentence denotes The results showed that the 28-days negative conversion probability in ‘standard care’＋HCQ group was 85.4%, similar to the ‘standard care’ group (81.2%).
T187 2742-2843 Sentence denotes HCQ did not show additional benefits of viral elimination in patients with mild to moderate COVID-19.
T188 2844-2988 Sentence denotes However, the study could not evaluate the antiviral effect of HCQ at early stages of disease, which is a critical period of antiviral treatment.
T189 2989-3148 Sentence denotes In addition, viral RNA specimens were mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results.
T190 3149-3300 Sentence denotes Due to the small number of severe patients, this study could not provide evidence regarding the effect of HCQ on the disease progression or regression.
T191 3301-3537 Sentence denotes In another large observational study involving 1376 cases of COVID-19 from New York, 811 patients received HCQ (600 mg/2 times on the first day, then 400 mg once a day for 4 days) within 24 or 48 hours of admission and 565 did not [55].
T192 3538-3648 Sentence denotes This study found no correlation between HCQ use and significantly higher or lower risk of intubation or death.
T193 3649-3824 Sentence denotes However, in this study, even after the propensity score-matching, the diseases in patients receiving HCQ were more severe at baseline than those in the patients not receiving.
T194 3825-3974 Sentence denotes Notably, according to another recent study [56], low dose of HCQ reduced fatality of critically ill patients with COVID-19 without apparent toxicity.
T195 3975-4144 Sentence denotes This retrospective study included 550 patients who need mechanical ventilation, of which 48 received HCQ treatment (200 mg/2 times/day for 7 to 10 days) and 502 did not.
T196 4145-4435 Sentence denotes The fatalities of the HCQ group was significantly lower than no-HCQ group (18.8% vs 47.4%, P < 0.05), and the inflammatory cytokine IL-6 in the HCQ group decreased significantly from 22.2 (8.3 to 118.9 pg/mL) at the beginning of treatment to 5.2 (3.0 to 23.4 pg/mL) at the end of treatment.
T197 4436-4627 Sentence denotes The authors deemed that the anti-inflammatory effect of low-dose HCQ and the activity of inhibiting viral replication may have important significance in critically ill patients with COVID-19.
T198 4628-4740 Sentence denotes Yet, this study is flawed due to its retrospective nature and the small number of HCQ treated patients included.
T199 4741-5005 Sentence denotes In short, some initial studies have shown that HCQ appears to have a curative effect on patients with mild COVID-19, but subsequent studies indicate that HCQ had no significant benefit in COVID-19 patients with viral conversion and the risk of intubation or death.
T200 5006-5220 Sentence denotes Although some recent studies show that low-dose HCQ could potentially reduce the mortality of severe COVID-19 patients, there are other studies showing that the HCQ use had no effect on risk of intubation or death.